Labs / CDMO: development & manufacturing
Iasobio
Nanjing, China · iasobio.com
GMP
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
IASO Bio is a commercial-stage biopharmaceutical company founded in 2017 that develops cell therapies and biologics for hematologic malignancies and autoimmune diseases. It has operations in Nanjing and Shanghai in China, and in Pleasanton, California, with capabilities spanning discovery, development, manufacturing, and commercialization.
Their website has a general contact form; we send your quote request through it.
What they offer
Fully Human Antibody Discovery Platform
Uses a fully human antibody library, a synthetic antibody library, and a single-domain antibody library to support antibody discovery and next-generation therapeutic development.
High-throughput CAR-T Cell Therapy Screening and Optimization Platform
Combines single-cell analysis and next-generation sequencing to screen and optimize CAR-T candidates based on phenotypic and functional metrics.
In Vivo CAR-T Platform
Develops in vivo CAR-T therapies using engineered viral vector surface proteins, T cell-specific promoters, and envelope modifications.
Advanced Manufacturing and CMC Platform
Supports plasmid development and production, lentiviral vector development and production, and FAST CAR-T development across the product lifecycle.
Clinical Development and Clinical Translational Research Platform
Operates a joint laboratory with a top-tier Chinese hospital to integrate research and clinical development.
Plasmid manufacturing
Produces plasmids using fermentation and purification technologies for Escherichia coli, with in-process analytics and sterile filtration.
Lentiviral vector manufacturing
Produces lentiviral vectors in a closed-system, automated, and scalable platform with release testing for identity, potency, sterility, residual DNA, and host-cell protein.
Cell product process development and GMP manufacturing
Develops cell products for GMP-compliant manufacturing with QC and QA systems for molecular detection, cell function, and flow cytometry.
What they work on
- Modalities
- Antibody, Bispecific, mRNA, Viral vector, Cell therapy, Gene editing, Plasmid DNA, LNP / formulation
- Assays and studies
- single-cell analysis, next-generation sequencing, molecular detection, cell function testing, flow cytometry, identity testing, potency testing, sterility testing, residual DNA testing, host-cell protein testing
- Scale and capacity
- fully integrated platforms spanning the entire product lifecycle, over 240 billion antibodies in the fully human antibody library, ten products and product candidates, four global R&D and manufacturing sites, Nanjing facility: approximately 7,866 square meters, Shanghai facility: 32,306 square meters
- Therapeutic areas
- hematological malignancies, autoimmune diseases, multiple myeloma, B-cell malignancies, myasthenia gravis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, B-cell non-Hodgkin lymphoma
- What to send
- single intravenous infusion of IASO208 · patients are not required to undergo conventional apheresis or lymphodepleting conditioning
- Type
- CRDMO
- Sites
- Nanjing, China · Shanghai, China · Pleasanton, CA, United States
- Quality
- Drug Manufacturing License (Nanjing facility, granted in February 2022) · global regulatory standards (lेंटiviral vector batch release and manufacturing platform) · injectable-grade standards (plasmid production) · GMP-compliant (cell product process development)
- Serves
- China, United States, Singapore, Hong Kong, Japan, Australia, Korea
- Address
- 1 Xinjinhu Road, Jiangbei New District, Nanjing, Jiangsu Province 210018
- Founded
- 2017
Similar labs. Asimov, Probiocdmo, Kyinno Bio, Unchained Labs
Found in a contract services directory. Listing built from iasobio.com. Work here? Claim this listing.